Scholars Central

Conference abstractPublished 21 Oct 2013

Corporate quality culture and marketing ethics: Where are those heading?

Authors: Mohammed R. Khan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Going back in times, patented medicines were commonplace in the United States. Cure-alls such as Snake oil were abundantly used, while ova of Tape Worm were packaged and sold for the treatment of obesity! In contrast, today?s pharma industry is believed to be based on sound ethical foundations, and is expected to deliver quality offerings to the consumer that are safe and effective when used appropriately. And in common with all successful businesses, pharmaceutical establishments are also expected to keep the shareholders satisfied by providing adequate return on investment, while also remaining competitive in the marketplace. The emerging picture however is not that rosy. Without distinction of size and origin, the industry is displaying a pattern that poses great cause for concern. Print media abounds with reports of Non-Compliance of GMP standards, falsification of data and test results, false claims related to blockbuster drugs, paying billions in fines to settle bribery, fraud, kickbacks, and improper marketing allegations. These are not isolated incidences but a sort of emerging trend that appears to suggest gradual degradation of the quality culture and marketing ethics. It is indeed a wakeup call!

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Mohammed R. Khan”